From www.bloodjournal.org by guest on January 26, 2015. For personal use only. Separation of Myeloid and Erythroid Progenitors Based on Expression of CD34 and c-kit By Marg 0. De Jong, Gerard Wagemaker, and Albertus W. Wognum In this repolz, a novel approach is described t o physically separate erythroid progenitors from monocyte and granulocyte progenitors, basedon the expression of CD34 and Kit. Using biotin-labeled human Kit ligand (KL) andflow cytometry, Kit was detectable on 2% to 3% of the nucleated cells in rhesus monkey bone marrow. Combination of biotin-KL with CD34 monoclonal antibodies (MoAb) showed that Kit was expressedon subsets of CD34"" and CD34P"" cells. Our data clearlydemonstratethat CD34wscells are more heterogeneous with respect t o Kit expression than observed in studies using Kit MoAb. A small cluster, approximately 7% of the CD34P0* cells, expressed CD34 at submaximal levels and stained brightly with biotinylated KL. This CD34Pos/kithi fraction contained predominantly erythroid progenitors (burst-forming units-erythroid; BFU-E). The majority of the granulocytic and monocytic progenitors (colony-forming units-granulocytelmacrophage; CFU-GM) were CD34P0*/ kitmed.Some BFU-Ewere also detected in theCD34P"'/kitmod and CD34'0w/kitPo'fractions at low frequency. In the latter subset, most erythroid colony-forming units (CFU-E) were recovered. Using three-color flow cytometry, we analyzed expression ofKit in relation to thatof CD34 and the class II major histocompatibili antigen, RhLA-DR. Themost immature bone marrow cells that can be identified in vitro, ie, CD34Po'/RhLA-DR'ow cells,were kitmed.The CD34Po'/kith' and CD34Po'/kit"agsubsets predominantly contained the more mature RhLA-DRb"'" cells. Ourresults demonstratethat erythroid precursors express c-kit at much higher levels than monomyeloid precursors and pluripotent progenitors. The difference in expression levelsof CD34 and c-kit can be exploited to isolate BFU-E populations that are virtually devoid of nonerythroid cells. 0 1995 by The American Societyof Hematology. T cell de~elopment."~"~~ In vivo administration ofKL leads to a dose-dependent expansion of both primitive and differentiated progenitor cells in the bone marrow (BM) of mice, nonhuman primates, or human patients. As a result, mobilized progenitors appear in the peripheral blood. At the same time, there is an increase in the number of mature cells of multiple lineages.*'"' The combined in vitro andinvivo activities of KL indicate that it acts on primitive progenitors as well as more differentiated lineage-committed cells. Studies with monoclonal antibodies (MoAb) against Kit have provided information about the cellular distribution of c-kit on murine and human cells. In humans, Kit is expressed on a large fraction of BM cells that express CD34, an antigen specific for early hematopoietic cells, including stem cells and multipotent and lineage-committed progenitor cells." The CD34P""/kitP"'fraction includes cells that coexpress surface proteins characteristic for differentiating progenitors (eg, CD33, CD38, CD71, and HLA-DR) but also developmentally immature cells that lack or express only low levels of these antigens.'R-44In keeping with this, the CD34P""/kitP"' subset contains committed monomyeloid and erythroid progenitors (colony-forming units-granulocyte/macrophage [CFU-GM] and burst-forming units-erythroid [BFU-E], respectively), as well as cells that produce clonogenic progeny in long-term cultures in the presence of cytokines or stromal feeder ~ e l l sSuch . ~ cells ~ ~were ~ ~undetectable ~ ~ or present at very low frequencies in the CD34Ykitnegfraction. Also, Kit has been detected on small subsets of CD34P"' BM cells that coexpress B (CD 10, CD19) or T (CD2, CD7) lymphoidspecific antigens, but the majority of B- and T-cell precursors appear to be kit"eg.3"4'.44 BFU-E and CFU-E differ in their responsiveness to stimulation by KL, or inhibition byKL MOA^,^^,^' indicating a declining role of c-kit during late stages of erythroid differentiation. In line with this, a decreasing Kit expression during differentiation of granulocytic, monocytic, and erythroid cells was shown by staining BM cells or cultured BFU-E progeny with '"I-labeled KL.'"4" However, the exact pattern of Kit expression especially during the early stages of differentiation remains unclear. This may partially be due to the HE C-KIT GENE encodes a type I transmembrane glycoprotein and is a member of the tyrosine kinase receptor family.' The ligand of Kit exists in both transmembrane and soluble forms and is variously known as mast cell growth factor, Steel factor, stem cell factor, and Kit ligand ( K L ) . 2 - 6 Both Kit (CD1 17) and its ligand are important for normal hematopoietic cell development in vivo, as demonstrated by the severity of hematopoietic defects in WiW mutant mice, which do not have functional C-kit,'.' andinSteelmutant mice, which lack active KL.'."'.' The molecular cloning of human and rodent KL has permitted detailed studies into the functional properties of this cytokine. The soluble form of KL, which consists of the Nterminal extracellular domain of the full-length transmembrane protein, is a poor stimulator of hematopoietic cells in vitro on its own. However, in the presence of other hematopoietic growth factors (HGFs), such as granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-3 (IL-3), and erythropoietin (EPO), KL enhances proliferation and differentiation of immature hematopoietic cells as well as monomyeloid and erythroid progenitors.'"-24In addition, KL affects the development of early lymphoid cells in the presence of IL-7, but is inactive at later stages of T- and B- From the Institute of Hematology, Erasmus University, Rotterdam, The Netherlands. Submitted April 11, 199.5; accepted July 20, 1995. Supported by the Netherlands Cancer Foundation Koningin Wilhelmina Fonds, the Dutch Organization,for Scientijic Research W O , the Royal Netherlands Academy of Arts and Sciences and Contracts of the Commission of the European Communities. Address reprint requests to Albertus W. Wognum, PhD, Institute of Hematology, Rm Ee1387A, Erasmus University, PO BOX 1738, 3000 DR Rotterdam, The Netherlands. The publication costsof this article were defrayedin part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. section 1734 solely to indicate this fact. 0 1995 by The American Society of Hematology. 0006-4971/95/8611-0020$3.00/0 4076 Blood, Vol 86, No 11 (December l ) , 1995: pp 4076.4085 From www.bloodjournal.org by guest on January 26, 2015. For personal use only. c-kit DISTRIBUTION ON HEMATOPOIETIC CELLS 4077 centrifugation for 30 minutes at 2,000 rpm at room temperature over a discontinuous bovine serum albumin (BSA) density gradient6' consisting of 25%, 23%, 22%, 21%, and 17% (wt/vol) BSA in 0.2 moln Tris-buffer/phosphate buffer, pH 7.2. Fractions were collected the Kit MoAb. In addition, some Kit MoAbs inhibit outand washed in HH. Erythrocytes were lysed using 10 mmoln potasgrowth of KL-responsive ~ e l l which s ~may~ impede ~ ~ ~sium~bicarbonate, ~ ~ ~155 mmol/L ~ ~ ammonium chloride, pH 7.4, confunctional characterization of purified kitPo' subsets. Detectaining 0.1 mmol/L EDTA. tion methods based on binding of the ligand itself provide Immunocytochemical staining and jlowcytometry. Cells were more reliable information about the capacity of cells tobind stained overnight on ice with biotin-KL (1 nmoVL) in HHcontaining 2% (voVvol) fetal calf serum, 2% (voUvol) rhesus monkey serum, and respond to a specific ligand than the use of receptor MoAbs. Biotin-labeled growth factors have been used exten- 0.05% (wt/vol) sodium azide, and DNAse (0.5 mglmL). Similar results were obtained by incubation for 2 hours on ice. Specificity sively to study the expression of functional growth factor of binding of the biotin-KL samples was determined by incubating receptors on BM ~ e l l s ! ~ - ~In ~ the present study, we have the cells with biotin-KL in the presence of either the blocking Kit biotinylated recombinant humanKL and examined the distriantibody SR-I (ascites 1:200 dilution; provided by Dr V. Broudy, bution of functional receptors forKL on rhesus monkeyBM University of Washington, Seattle, WA) or a 100-fold molar excess cells. With this method, we show that erythroid progenitors of unbiotinylated KL. The cells were incubated for 30 minutes on can be distinguished and physically separated from immature ice with streptavidin-phycoerythrin (streptavidin-PE, I: 150 vol/vol; multipotent cells and committed monocyte and granulocyte Molecular Probes, Eugene, OR). After each incubation the samples progenitors on the basis of CD34 and kit expression. were washed in HH with fetal calf serum and azide. Fluorescence signals were amplified by incubating the cells for 30 minutes on MATERIALS AND METHODS ice with biotinylated PE MoAb and streptavidin-PE, as described earlier." During the last streptavidin-PE incubation, cells were douBiotinylation. Recombinant human KL (a gift from Dr S. Gillis, ble-stained with a CD34 MoAb (antibody 566; provided by Dr T. Immunex, Seattle, WA)'was biotinylated using biotin-N-hydroxy Egeland, The National Hospital, Oslo, Norway) thatwas labeled succinimide ester (NHS-Biotin; Pierce, Rockford, IL) as described with fluorescein isothiocyanate (FITC; Sigma) using standard procepreviously for other growth f a ~ t o r sBriefly, . ~ ~ ~NHS-Biotin ~ ~ ~ ~ ~disdures. For three-color analysis, cells were also incubated with a solved in dimethyl sulfoxide (DMSO) was added to IO-ng aliquots peridinin chlorophyll protein (PerCP)-labeled antibody against the of KL in 0.1 moVL carbonate-bicarbonate buffer, pH 8.4, containing human class I1 histocompatibility antigen HLA-DR (Becton Dickin0.02% (voVvol) Tween-20 at molar biotin:protein (BP) ratios of son, Mountain View, CA) that crossreacts with rhesus monkey IO: 1, 100: 1, or 300: 1. A control sample was incubated with DMSO RhLA-DR antigens. To study the expression of the transferrin recepwithout biotin. After 3 hours of incubation at room temperature in tor, double-staining experiments with biotin-KL and FITC-conjuthe dark, biotin-= molecules were separated from the remaining gated CD71 MoAb (Becton Dickinson) were performed. Sorted cells free biotin molecules in the samples by size exclusion chromatograwith low CD34 expression were incubated with FITC-labeled CD71 phy on a I-mL Sephadex G-25 column (Pharmacia, Uppsala, SweMoAb as well. den), equilibrated in phosphate-buffered saline containing 0.02% Samples were analyzed using a FACScan or sorted using a FACS (wt/vol) Tween-20. To test the efficiency of the biotinylation, biotinVantage (Becton Dickinson, San Jose, CA). Cells were illuminated KL was adsorbed onto streptavidin-agarose beads (Sigma, St. Louis, with the 488-nm line of an argon ion laser. Green FITC fluorescence MO), and the amount of biologic activity that remained in the superwas measured through a 530-nnd30-nm bandpass filter. Orange PE natant was determined. Biotin-KL was stored at -80°C in the presfluorescence was measured through a 575-nnd26-nm or a 585-nm/ ence of 0.02% (wt/vol) sodium azide. 42-nm bandpass filter. Red PerCP fluorescence was measured Biologic activiry assay. The biologic activity of biotin-KL was through a 650-nm longpass filter. Cells were analyzed in a light measured in a proliferation assay using cells from the human factorscatter window as indicated in Fig 2C to include cells with intermedidependent megakaryocyte cell line M07e.60.6'Cells were grown in intermediate ate to high forward light scatter (FLS) andlowto a-minimal essential medium (aMEM; GIBCO, Gaithersburg, MD) perpendicular light scatter (PLS) properties and to exclude granulosupplemented with 10%(vol/vol) fetal calf serum (FCS), 0.05 mmoV cytes, dead cells, and cellular debris. L P-mercaptoethanol, 5 ng/mL human IL-3, and 10% (voVvo1) conIn vitro culrure in semisolid medium. Sorted populations were ditioned medium of the 5637 cell line. Cultures were maintained at assayed for their content of CFU-GM, CFU-E, and BFU-E by in 37°C in a humidified atmosphere of 10% COz in air. To determine vitro colony formation in semisolid methylcellulose culture medium. the biologic activity of biotin-KL, 5 X IO' cells per well of 96-welI In 35-mm petri dishes (Becton Dickinson), unsorted cells were plated microtiter plates (Falcon 3072; Becton Dickinson Labware, Lincoln at a concentration of 50,000 per dish; sorted subsets were plated at Park, NJ) were cultured in 200 p L medium containing serial dilutions 10,000 per dish (for cells from the light scatter window as shown of growth factor. The cells were cultured for 40 to 48 hours, after in Fig 2C) or at 500 to 1,O00 per dish (for subsets of CD34P"scells) which0.25 pCi 3H-thymidine was added to each well. The cells in I mL methylcellulose medium as de~cribed.'~Methylcellulose were harvested after 16 to 18 hours of thymidine incorporation, and cultures included the following components: 0.8% (wt/vol) methylthe radioactivity was measured in a liquid scintillation counter. At cellulose in aMEM (GIBCO), 5% (vol/vol) FCS, 1.5% (wt/vol) a B P ratio of l O : l , KL retained all of its biologic activity, while BSA, 10 pglmL insulin, 0.6 mglmL human transferrin, 15 pmoVL the biotinylation efficiency was greater than 99%. as determined by linoleic acid, 15 pmoln cholesterol, 0.1 mmoVL P-mercaptoethanol, adsorption onto streptavidin-agarose beads. This preparation was used for further experiments. 0.1 pmollL sodium selenite, 1 mg/mL nucleosides, 1 0 0 U/mL penicillin, and 50 pg/mL streptomycin. Recombinant rhesus monkey Low-densig BM cell preparation. BM aspirates from young IL-3 was used at a final concentration of 30 ng/mL, human recombiadult rhesus monkeys (Macaca mularra) from the TNO Primate Center, Rijswijk, The Netherlands, were collected in Hanks' HEPES nant GM-CSF (Behringwerke AG, Marburg, Germany) at 5 ng/mL, buffered salt solution (HH) with heparin and DNAse. The buffy coat human KL at 200 ng/mL, G-CSF at 100 nglmL, and human recombifraction was collected after centrifuging the cells for 15 minutes at nant EPO (Behringwerke AG) at 4 U/mL. CFU-GM cultures were 2,500 rpm at room temperature. Low-density cells were obtained by grown in the presence of IL-3, GM-CSF, and KL, with or without differences in techniques and reagents used to detect and isolate Kit-expressing cells. The ability to distinguish kitneg, k i t I O W , and kithi cells is influenced by the binding affinity of From www.bloodjournal.org by guest on January 26, 2015. For personal use only. 4078 DE JONG, WAGEMAKER, AND WOGNUM I 0 r h k b i o t i n - K L A\ r 11. I I , o,75b KL + biotin-KL 0 I l’ I t l l l o,8% anti-Kit + biotin-KL 0 I l I 0.2% 0 IO’ 10’ IO‘ 10’ lo’ l00 lo’ 102 10‘ 103 PE-fluorescence K* Fig l . Expression of and specificity of biotin-KL staining on M07e and rhesus monkey BM cells. Cells wera sequentially stained with biotin-KL and streptavidin-PE. Rhesus monkey BM cells were double-stained with FITC-labeled CD34 MoAb and analyzed inside a liaht scatter window as indicated in Fig 2. (A) M07e cells, (B) rhesus monkey BM cells, and (C) CDWW rhesus monkey BM cells. Hlstograms rapresent (from top to bottom) cells incubated with biotin-KL, biotin-KL in the presence of a 100-fold molar excess of unlabeled KL, biotin-KL in the presence of the SR-1 anti-kit antibody, and control calls incubated without biotin-KL. Markers were set on tha basis of background fluorescance of unstained cells to indicate the percentages of k Pcells and to show the specificity of the binding of biotin-KL to the cells. adding G-CSF. BFU-E cultures were grown in thepresence of EPO, KL, and 0.2 mmoVL bovine hemin. CFU-E cultures were grown in the presence of EPO and 0.14 mmol/L hemin. Cultures were maintained in a humidified atmosphere of 10%CO2 in air. Colonies were counted at day 4 (CFU-E) and day 11 or 12 (CFU-GM and BFUE). Data of duplicate dishes were expressed as average number of colonies per 1,OOO cells plated. Standard errors were obtained by taking the square root of the absolute number of colonies counted, assuming that crude colony counts are Poisson-distributed.6’.” Incubation of the cells with biotin-= did not stimulate colony formation, because no difference in colony numbers was seen between cells that had and cells that had not been incubated with biotin-KL. In vitro culture in liquid medium. For liquid suspension cultures, an automated single-cell deposit unit (Becton Dickinson) was used to sort individual cells directly into separate wells of 96-well microtiter plates (Falcon 3072; Becton Dickinson Labware). In different experiments, either 1 or 1,000 cells were sorted into 200 pL culture medium per well. Cells were grown in aMEM without HGFs or supplemented with various combinations (final concentrations) of IL-3 (30 ng/mL), GM-CSF (5 nglmL), KL (200 nglmL), and EPO (4 U/&). In cultures started with one cell per well, half of the culture medium was replaced every week. Cells were expanded before reaching confluency by transfer to l mL medium in 24-well culture plates (Costar, Cambridge, MA). Phenotypic analysis was performed by staining with antibodies against CD34, CD71, CDllb, and HLA-DR, followed by FACScan analysis. In cultures started with 1,000 cells per well, separate cultures wereused for ‘H-thymidine incorporation after 3, 5, or 7 days of culture and for phenotypic and morphologic analysis of cells produced after 7 days of culture. RESULTS Biotin-KLstaining of MO7e cells andrhesus monkey BM cells. Cytochemical staining properties of biotin-= on M07e cells and on rhesus monkey BM cells were studied usingflow cytometry. All cells of the KL-responsive cell line M07e and a fraction of the BM cells were stained brightly with biotin-= in combination with PE-conjugated streptavidin (Fig 1A and B). Because the number of kitws cells in unfractionated BM was very low (2% to 3% of the nucleated cells, corresponding to 7% of the cells inside the light scatter window, indicated in Fig 2), Kit expression was also studied on cells inside a window based on high CD34 expression (Fig 1C). Within the CD34P”Ssubset, 30% of the cells were kitw’. The fluorescence signal of M07e as well asBM cells, incubated with biotin-KL in the presence of‘ either unlabeled KL or the blocking anti-Kit antibody SRwas almost identical to that of control cells incubated without biotin-KL. This indicated that binding of biotin-KL to these cells was specific and due to binding to Kit. Distribution of c-kit on rhesus monkey BM cells. Because of the low frequency of kitP”’cells in unfractionated BM (Fig l), the relation between CD34 and Kit expression was studied on low-density BM cells (Fig 2). Expression of Kitwas detectable on 15.2% ? 6.1% (three different experiments) of the low-density BM cells inside the light scatter window indicated in Fig 2. Combination of biotinKL with CD34 MoAb showed that 30% to 50% of these kitpositive cells were CD34-positive. The CD34p” cells were heterogeneous with respect to Kit expression. A small subset, containing 7% of the CD34P”scells, expressed high levels of c-kit (region 1 inFig 2A). CD34 expression on these CD34Vkithi cells was lower than on another subset that expressed Kit at intermediate levels (CD34ws/kit”ed;region 2 ) . which indicated that the latter population included the more immature cells. This kitmd fraction contained more than 60% of the CD34P””cells. The remainder of CD34P”’ cells had no detectable Kit expression (CD34P”s/kitneg; region 3). Finally, a subset of cells with low CD34 expression ex- From www.bloodjournal.org by guest on January 26, 2015. For personal use only. c-kit DISTRIBUTION ON HEMATOPOIETIC CELLS 1A I" 4 I g c 1000 D 1o4lB a excess KL - I Q II 1 4079 103 region 3 I 4 region 4 loo 10' IO* 103 CD34 expression lo4 0 400 800 forward light scatter l" loo lo1 IO* lo3 lo4 RhLA-DR expression Fig 2. Expression of CD34 and Kit onrhesus monkey BM cells, light scatter properties and RhLA-DR expression of different subsets. Lowdensity rhesus monkey BM cells, stained with biotin-KL and streptavidin-PE and counterstained with FITC-labeled CD34 MoAb and PerCPlabeled HLA-DR MoAb after amplification of the fluorescence signal, were analyzed by flow cytometry. (A) Dot plot of kit versus CD34 expression. The rectangular boxes indicate the windows used t o sort cells on the basis of CD34 and Kit expression levels. (B) Nonspecific binding of biotin-KL was evaluated in the presence of a 100-fold molar excess of unlabeled KL. The horizontal line is set on the basis of background fluorescence of unstained cells to discriminate between brightly stained cells and cells with low or no Kit signal. (C) PLS versus FLS of low-density cells and of cells in theregions 1 through 4as identified in A. Indicated is thescatter window that wasused in thesorting experiments t o include cells with intermediate t o high FLS and low to intermediate PLS properties and to exclude granulocytes, dead cells, and cellular debris. (D) RhLA-DR fluorescence histograms of cells in the same regions as in (C). pressed c-kit in a range from low to high. Most cells in this region, particularly those with high Kit expression, showed a small shift in fluorescence intensity after staining with the CD34 MoAb, as compared with cells stained with isotypecontrol MoAb. Therefore, this subset was designated CD34'"" (CD34'"W/kitPo';region 4). As shown in Fig 2C, CD34P"'/kith' and CD34P"'/kitn"dcells (regions 1 and 2) displayedlight scatter properties characteristic of immature, blast-like cells, ie, intermediate to high FLSandlowPLS. CD34P"s/kit"s and CD34'""/kitP'" cells (regions 3 and 4) were more heterogeneous with respect to light scatterand also containedcells withrelatively high PLS. Additionally, small cells with low FLS were found in the CD34P"'/kit""gfraction (region 3). Analysis of RhLA-DR expression on thedifferent subsets (Fig 2D) indicatedthat most of the CD34P"'/kith'and CD34""'/ kitnegcells (regions 1 and 3) were RhLA-DRhrIgh',whereas the CD34P"s/kit""dcluster (region 2) contained RhLA-DRbrLghh' and RhLA-DRd"" cells at almost equal frequencies. The presence of RhLA-DRd"" cells in region 2, in combination with the high CD34 expression of this subset, indicated that very immaturecellsexpress Kit at low tointermediate levels. RhLA-DR expression was alsolow on theCD341""/kith' cells, but these represent relatively mature cells, as CD34 levels on these cells were very low. Colony-forming potential of different fructions q f rhesus monkey BM. We assayed the functional abilities of the subsets, discussed in the previoussection, in standardcolony assays in semisolid culture media. The results of two such experimentsareshown in Table 1. Most CFU-GMwere found in the CD34P"'/kit'"edfraction, which was 20 to 30 times enriched in CFU-GM as compared with the low-density cells. A much lower proportion of CFU-GM was recovered in the CD341"'"/kit""S subset, and less than 1% of the CFU-GM were found in the CD34P"'/kit'" fraction. The CD34P"'/kit'" fraction contained at least 30-fold more BFU-E than CFU-GM. As shown in Table 1 , 200 to 400 of every 1,000 CD34P"s/kith'cells developed into a BFU-E colony, compared with one to three of every 1,000 low-density cells, demonstratinganenrichment of 100- to 200-fold. From www.bloodjournal.org by guest on January 26, 2015. For personal use only. 4080 WOGNUM DE JONG, WAGEMAKER, AND Table 1. Colony Formation In Vitro of Different Sorted Fractions of Low-Density Rhesus Monkey B M Cells BFU-E CFU-GM 1 No. of Colonies/ io3cells % Fractlon Sorted Experiment Region A 2 3 4 B 1 2 3 4 CD34PoE/kith' CD34P"s/kitme" CD34PoS/kit"eQ CD34'0w/kitP"s density Low CD34pos/kith' CD34PoS/kitmed CD34Pos/kit"eQ CD34'""/kitPoS fraction Scatter % Recovery 0.33 419.3 14.5 0.5 i- 2.7 3.89 181.5 i- 9.5 2.06 16.0 i- 2.8 3.70 0.0 -+ 0.0 100 9.3 t 0.2 0.45 0.0 i- 0.0 3.30 101.5 t 7.1 2.65 13.5 i- 2.6 5.88 0.0 i- 0.0 100 3.6 t 0.4 75.9 3.5 0.0 100 0.0 93.0 9.9 0.0 100 No. of Colonies/ io3 cells 21.0 0.0 18.0 3.2 188.0 3.5 0.0 0.5 1.1 t 36.9 t 3.2 i- 0.0 t 3.0 i- 0.3 t 13.7 i- 1.3 t 0.0 i- 0.5 i- 0.4 CFU-E % Recovery 43.2 25.5 0.0 20.8 100 76.9 10.5 0.0 0.0 2.7 100 No. of Colonies/ io3 cells % Recovery 48.8 0.5 2 3.1 0.0 t 0.0 0.0 2 0.0 133.3 ? 5.2 29.9 i- 0.5 39.0 i- 11.3 0.0 i 0.0 i- 0.0 13.0 2 4.6 2.6 t 0.7 0.0 0.0 16.5 100 6.8 0.0 0.0 29.4 100 Cells inside a light scatter window as shown in Fig2C were sorted on the basis of CD34 and kit expression into regionsas shown in Fig2A. B) are shown. Data from duplicate dishes are expressed as average number of colonies Results of two independent sorting experiments (A and per I O 3 cells plated t SE (the square root of the absolute number of colonies counted; see Materials and Methods). Recovery was calculated as shown in Fig 2C relative to the unsorted low-density fraction (experiment A), or relative to the fraction sorted inside a light scatter window (experiment B) SomeBFU-E were detected in the CD34pos/kit"'"dand the CD34'""/kitP"' fractions, but at 20- to 50-fold lower frequencies than in the CD34p"'/kith' fraction. The erythroid origin of kith' cells was confirmed by double-staining of cells with biotin-KL and CD71 MoAb, which showed that kith' cells expressed high levels of the transferrin receptor (Fig 3). The number of CFU-E colonies recovered after sorting was very low (Table I). Most of the CFU-E were present in the CD34'""/kitp''" fraction, suggesting thatthisfraction contained differentiating erythroid cells. In agreement with this, erythroblasts were the predominant cell type identified in cytocentrifuge preparations from this fraction (data not shown). Moreover, restaining of sorted CD34'""/kitp"s cells with CD71 MoAb showed high CD71 expression on these cells (Fig 4). However, because of the low CFU-E recovery, we cannot exclude the possibility that CFU-E were present in other subsets as well. Growth fuctor responses in liquid culture. To study the effect of different growth factors on theshort-term proliferation and differentiationof the varioussubsets, 1,000 cells per well were sorted into liquid medium containing different (combinations of) cytokines. The highest proliferation was found in the wellswith cellsfromthe CD34po'/kit'"edand CD34P"s/kith'fractions when cultured in the presence of KL IL-3 + GM-CSF.FACS analysis of the differentfractions after7 days of cultureshowed mainlyerythroid (CD7 I P"'/CDl 1b'lcg/RhLA-DKeg) cellsin the CD34""'/kith' 1 '""/CD 1 l bpYRhLA-DWeg) fractions, and granulocytic (CD7 and monocytic (CD7l'""/CDl lbPos/RhLA-DRPO") cells in the CD34p'"/kit'""dfractions. Examples of CD71 and RhLA-DR expression oncultured erythroid cells andon cultured granulocyte and monocyte precursors are shown in Fig 5A and B, respectively. In agreement with these findings, cytospin preparations showed cells from the erythroid lineage in the CD341""/kitp'" and CD34pos/kith' cell cultures, and monomyeloid cells in the CD34P"s/kit'ncdand CD34P"'/kit"eg cell cultures (data not shown). To further characterize the long-term differentiation potential of the various fractions, individual cells were sorted directly into separate wells of 96-well microtiter plates and + l o 4T lo3 102 101 100 loo 10' 102 io3 1 transferrin receptor (CD71) expression Fig 3. Expression of CD71 and Kit on low-density rhesus monkey B M cells. Cells were stained with biotin-KL, streptavidin-PE, and FITC-labeled CD71 MoAb. (A) Dot plot of kit versus CD71 expression of cells inside the scatter window as indicated in Fig 2C. (B) Nonspecific binding of biotin-KL was evaluatedin the presence of a 100-fold molar excess of unlabeled KL. From www.bloodjournal.org by guest on January 26, 2015. For personal use only. c-kit DISTRIBUTION ON HEMATOPOIETIC CELLS 4081 l Table 2. Proliferation of Different Subsets of CD34P"' Low-Density Rhesus Monkey BMCells No. of Wells (of a total of 192) Phenotype Proliferating Expanded Fraction Region 1 2 3 1oo l 0' I o3 IO2 I o4 FITC fluorescence intensity Fig 4.CD71 expression on sorted CD34'ow/kitPo'rhesus monkey BM cells. Low-density BMcells, stained with biotin-KL, streptavidinPE, and FITC-labeled CD34 MoAb, were sorted in a window similar to that of region 4 in Fig 2A. Subsequently, half of the sample was incubated with buffer only (thin line) and the other half, with FITClabeled CD71 MoAb (bold line), and reanalyzed. cultured in the presence of IL-3, GM-CSF, and KL for a period of 4 weeks. No significant difference was seen betweencultures with and without EPO (data not shown). Ninety percent of the wells with CD34P"s/kith'cells and 8 1% with CD34Pos/kit'"d cells contained proliferating cells, whereas only 33% of the CD34Pos/kitneS cells showed proliferation (Table 2). There was a large difference between the fractions with respect to the amount of cells produced in the wells and the nature of these clones. In general, the kith' clones proliferated faster and were exhausted sooner than the kitmedclones, which continued to grow up to 4 weeks after sorting. The number of cells in the kitnegclones remained very low. Microscopic inspection of the wells showed erythroid cells in the kithi clones and granulocytic Fig 5. Phenotypic analysis of cultured fractions of rhesus monkeyBM cells. Low-densityBM cells were stained with biotin-KL, streptavidin-PE, and FITC-labeled CD34 MoAb. Cells (1,000 per well) were sorted on the basis of CD34 and kit expression, as indicated by the regions in Fig 2A. Sorted cells were cultured in medium in the presence of KL + 11-3 GMCSF. After 7 days of culture, the cells were incubated with FITClabeled CD71 MoAb and PE-labeled HLA-DR MoAb and analyzed by flow cytometry. Shown are cultures thatwerestarted with CD34Po'/kithi (A) or CD34P0"/ kitmd (B) cells. 4"' CD34pos/kithi CD34poS/kitmed CD34P"s/kitn'a 173 155 64 130 51 0 E G M 46 0 1 4 0 2 Cells were incubated with biotin-KL and CD34 MoAb and sorted one cell per well into liquid medium containing IL-3, GM-CSF, and KL with or without EPO. Wells in which proliferation occurred were counted. Before reaching confluency, clones with extensive proliferation were then expanded into l-mL cultures. Expanded clones that contained sufficient numbers of cells were stained with antibodies against CD71, CDllb, and HLA-DR. Abbreviations: E, erythroid (CD71P"s/CD11b"eg/RhLA-DRP0S); G, granulocytic (CD71'"w/CD11bPoS/RhLA-DR"eg); and M, monocytic ~CD7110W/CD11bPoS/RhLA-DRPoS). and monocytic cells in the kitmedand kitnesclones. About 25% of the wells with kith' cells (Table 2) proliferated sufficiently to perform a FACS phenotyping experiment, resulting in46 erythroid (CD71P"') and one granulocytic (RhLA-DR"es/CD1lbP"")clone. Only 6 of 192 wells with kitmd cells contained enough cells to be analyzed in this way, resulting in four granulocytic (RhLA-DRneg/CD1lbpos) and two monocytic (RhLA-DRP"'/CD1lbP"') clones. DISCUSSION Expression of Kit on r n ~ r i n e ~and ~ - h~ * ~ m a BMn ~ ~ cells has been studied extensively using Kit-specific MoAb. However, the exact expression pattern of Kit during the early stages of hematopoietic cell differentiation especially is still not clear. Differences between published results may partially be explained by the use of different MoAbs, because the ability to distinguish kith', kitmsd,and kit'"" cells is influenced by the binding affinity of the Kit MoAb. Moreover, as Kit MoAb can inhibit outgrowth of kitPusce11s~o~42~46~47 It . A + CD71 (transferrin receptor) expression From www.bloodjournal.org by guest on January 26, 2015. For personal use only. 4082 is possible that the kitws cells do not develop optimally in culture if high-affinity MoAbs are used for sorting. This would lead to a serious underestimation of the number of colony-forming cells in the kitPossubset. Cell staining methods based on the ligand itself cause no such inhibition. In addition, such methods by definition provide more reliable information about the capacity of the cells to bind and respond to a specific ligand than staining with MoAb against the receptor. In this study, we have used biotinylated KL to examine the expression of Kiton subsets of low-density rhesus monkey BM cells. We were able to detect Kit on 2% to 3%of the nucleated cells, similar to frequencies previously obtained for human BM using Kit MOA^.^'.^' Double-staining with biotin-KL and CD34 MoAb showed Kit expression on subsets of CD34PoSas well as CD34'"" rhesus monkey BM cells. A small fraction of CD34P"scells with a high Kit expression was detected, consisting almost exclusively of BFL-E. In line with this, CD34Tkith' cells produced erythroblasts in liquid suspension cultures, and the kith' cells expressed high levels of the transferrin receptor. Some BFU-E were also found in the kitmedpopulation. This might reflect insufficient separation of this subset and the kith' cells, although the kith' cells are quite a distinct cluster. It is also possible that these kitmedcells represent a separate population, eg, one that is more immature than the kithiBFU-E, because the kith' cells express CD34 at a lower level than the kitmd population. Heterogeneity within the BFU-E population has also been observed by Simmons et al," who detected a small CD34p0s/ kitnegBFU-E fraction in sorting experiments using kit MoAb YB5.B8. Using another MoAb, NU-c-kit, Gunji et a14*separated CD34POSBM cells into kith', kit'"", and kitnegsubsets. In contrast with our results, these investigators found the highest BFU-E frequencies in the kit'"" subset, whereas BFU-E frequencies in the kithisubset were very Unfortunately, no information was provided about the overall BFU-E recovery in the sorted fractions, so it cannot be ruled out that colony formation by kith' cells was underestimated. This might be in accordance with results reported by Broudy et al,40 who showed that outgrowth of a small subset of human BFU-E is not inhibited by the Kit antibody SR-1. Such inhibition apparently does not occur with cells stained with biotinylated KL, as demonstrated by the high recovery of BFU-E and CFU-GM after sorting (Table 1). Most CFU-E were present in the CD34'ow/kitP"s fraction. This population was almost completely erythroid, as demonstrated by high CD7 1 expression. The results indicating that BFU-E as well as CFU-E display Kit correlate well with the insufficient erythropoiesis and the occurrence of macrocytic anemia in WIW mutant mice, which do not have functional c-kit. Also in accordance with these results, Papayannopoulou et aP9 and Ashman et a13' have shown that BM cells that had been isolated via either immune adherence to the SR-1 antibody or immune rosetting using the YBS.B8 antibody were highly enriched for erythroid cells. Binding studies with Iz5I-KL on cultured BFU-E progeny showed that proerythroblasts labeled much more densely than erythrob l a s t ~Although .~~ Kit is present on both BFU-E and CFUE, KL is necessary only for BFU-E outgrowth, but not for DE JONG,WAGEMAKER, AND WOGNUM CFU-E and later erythroid cell^.^.^^ Collectively, the data suggest that Kitexpression reaches its maximum at the BFUE stage and gradually declines during terminal erythroid differentiation. This pattern of Kit expression appears similar to that of CD7I7' and the EPO receptor.55." The CD34P"s/kit"egfraction contained virtually no colonyforming cells. Although the presence of very immature cells in this fraction cannot be ruled out completely, most of the cells in this subset are more mature, based on the relatively low CD34 and high RhLA-DR expression, characteristic of activated and differentiating cells. These CD34Ykitnegcells appear to represent primarily monocyte and granulocyte precursors. In addition, part of the CD34pos/kit""g fraction has low FLS and PLS properties and probably consists ofBlymphocyte precursor cells. In previous studies, Kit has been detected ononly small subsets of CD34P"s/CD10Pos and CD34Pos/CD19p'B-lymphocyte precursors.u This is consistent with an involvement of KL in early but not later stages of B-cell d e ~ e l o p m e n t . ' ~ ~ ~ ~ ~ ~ ~ . ~ ' Part of the CD34ps/kitm"dcells showed high CD34 and low RhLA-DR expression, a phenotype that has previously been associated with the most immature cells that canbe identified in human BM.45.74.75 Recently, we have shown that the CD34PoS/DRd"" rhesus monkey BM subset contains multipotential progenitors with high proliferative capacity." Preliminary results from transplantation experiments indicate that the cells that can reconstitute lethally irradiated rhesus monkeys are also present in this subset. In accordance with the expression of Kit on immature rhesus monkey BM cells, murine BM cells expressing Kit were enriched for hematopoietic stem ~ e l l s . ~ ~These , " , ~ ~results support the conclusion that Kit is already expressed at low to intermediate levels at a very early stage of hematopoiesis. Further studies focusing on subsets of CD34ws/kitmed/RhLA-DRd"" rhesus monkey BM cells will be useful to establish the importance of individual hematopoietic growth factors during stem cell proliferation and differentiation, and to provide candidate stem cell fractions for transplantation studies. In summary, our data are consistent with a model in which immature, multipotent progenitors are CD34Ykitmd. Along the monomyeloid lineage, these cells differentiate into CD34pos/kitmd CFU-GM. Expression of Kit declines after the CFU-GM stage, and the cells lose CD34 expression. Along the erythroid lineage, CD34p"s/kitmed progenitors differentiate to kith'BFU-E, which gradually lose CD34 when they differentiate into CD34'""/kith' CFU-E. This is followed by a gradual disappearance of Kit expression during terminal differentiation into mature red blood cells. The ability to distinguish the CD34po'/kith1population provides a methodto obtain highly enriched BFU-E populations that are devoid of nonerythroid cells. ACKNOWLEDGMENT We thankDrs S. Gillis (Immunex, Seattle, WA) forthe gift of KL, T. Egeland (University Hospital, Oslo, Norway) for supplying CD34MoAb 566, and V.C. Broudy (University of Washington, SR-l. We are grateful to K.J. Seattle, WA) for thekitantibody Neelis,M. van Teeffelen, and H. Wiersema for providing bone marrow aspirates and to H. Busking-van der Lelij, W. Dimjati, D. From www.bloodjournal.org by guest on January 26, 2015. For personal use only. c-kit DISTRIBUTION ON HEMATOPOIETIC CELLS Kieboom-Pluimes, T. Visser, and Y. Westerman for excellent technical assistance. We thank Dr W.A.M. Loenen for critically reading the manuscript. REFERENCES 1. Chabot B, Stephenson DA, Chapman VM, Besmer P, Bernstein A: The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature 335238, 1988 2. Anderson DM, Lyman SD, Baird A, Wignall JM, Eisenman J, Rauch C, March CJ, Boswell HS, Gimpel SD, Cosman D, Williams D E Molecular cloning of mast cell growth factor, a hematopoietin that is active in both membrane boundand soluble forms. Cell 63:235, 1990 3. Huang E, Nocka K, Beier DR, Chu TY, Buck J, Lahm HW, Wellner D, Leder P, Besmer P: The hematopoietic growth factor KL is encoded by the S1 locus and is the ligand of the c-kit receptor, the gene product of the W locus. Cell 63:225, 1990 4. Martin FH, Suggs SV, Langley KE, Lu HS, Ting J, Okino KH, Morris CF, McNiece IK, Jacobsen FW, Mendiaz EA, Birkett NC, Smith KA, Johnson MJ, Parker VP, Flores JC, Patel AC, Fisher EF, Erjavec HO, Herrera CJ, Wypych J, Sachdev RK, Pope JA, Leslie I, Wen D, Lin C-H, Cupples RL, Zsebo KM: Primary structure and functional expression of rat and human stem cell factor DNAs. Cell 63:203, 1990 5. Zsebo KM, Wypych J, McNiece IK, Lu HS, Smith KA, Karkare SB, Sachdev RK, Yuschenkoff VN, Birkett NC, Williams LR, Satyagal VN, Tung W, Bosselman RA, Mendiaz EA, Langley KE: Identification, purification, and biological characterization of hematopoietic stem cell factor from buffalo rat liver-conditioned medium. Cell 63:195, 1990 6. Zsebo KM, Williams DA, Geissler EN, BroudyVC, Martin FH, Atkins HL, Hsu RY, Birkett NC, Okino KH, Murdock DC, Jacobsen FW, Langley KE, Smith KA, Takeishi T, Cattanach BM, Galli SJ, Suggs SV: Stem cell factor is encoded at the S1 locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell 63:213, 1990 7. Geissler EN, Ryan MA, Housman DE: The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene. Cell 55:185, 1988 8. Flanagan JG, Leder P The kit ligand: A cell surface molecule altered in steel mutant fibroblasts. Cell 63:185, 1990 9. Copeland NG, Gilbert DJ, Cho BC, Donovan PJ, Jenkins NA, Cosman D, Anderson D, Lyman SD, Williams DE: Mast cell growth factor maps near the steel locus on mouse chromosome 10 and is deleted in a number of steel alleles. Cell 63:175, 1990 10. Bernstein A, Forrester L, Reith AD, Dubreuil P, Rottapel R: The murine W/c-kit and Steel loci and the control of hematopoiesis. Semin Hematol 28: 138, 1991 11. Broxmeyer HE, Hangoc G , Cooper S, Anderson D, Cosman D, Lyman SD, Williams DE: Influence of murine mast cell growth factor (c-kit ligand) on colony formation by mouse marrow hematopoietic progenitor cells. Exp Hematol 19:143, 1991 12. Broxmeyer HE, Cooper S, Lu L, Hangoc G, Anderson D, Cosman D, Lyman SD, Williams DE: Effect of murine mast cell growth factor (c-kit proto-oncogene ligand) on colony formation by human marrow hematopoietic progenitor cells. Blood 77:2142, 1991 13. Carow CE, Hangoc G, Cooper SH, Williams DE, Broxmeyer HE: Mast cell growth factor (c-kit ligand) supports the growth of human multipotential progenitor cells with a high replating potential. Blood 78:2216, 1991 14. McNiece IK, Langley KE, Zsebo KM: Recombinant human stem cell factor synergises with GM-CSF, G-CSF, IL-3 and epo to stimulate human progenitor cells of the myeloid and erythroid lineages. Exp Hematol 19:226, 1991 15. Metcalf D, Nicola NA: Direct proliferative actions of stem 4083 cell factor on murine bone marrow cells in vitro: Effects of combinationwith colony-stimulating factors. h o c Natl Acad Sci USA 88:6239, 1991 16. Migliaccio G , Migliaccio AR, Druzin ML, Giardina PJ, Zsebo KM, Adamson JW: Effects of recombinant human stem cell factor (SCF) on the growth of human progenitor cells in vitro. J Cell Physiol 148:503, 1991 17. Tsuji K, Zsebo KM, Ogawa M: Enhancement of murine blast cell colony formation in culture by recombinant rat stem cell factor, ligand for c-kit. Blood 78:1223, 1991 18. de Vries P, Brasel KA, Eisenman JR, Alpert AR, Williams DE: The effect of recombinant mast cell growth factor on purified murine hematopoietic stem cells. J Exp Med 173:1205, 1991 19. Brandt J, Briddell RA, Srour EF, Leemhuis TB, Hoffman R: Role of c-kit ligand in the expansion of human hematopoietic progenitor cells. Blood 79:634, 1992 20. Heyworth CM, Whetton AD, Nicholls S, Zsebo K, Dexter TM: Stem cell factor directly stimulates the development of enriched granulocyte-macrophage colony-forming cells and promotes the effects of other colony-stimulating factors. Blood 80:2230, 1992 21. Migliaccio G, Migliaccio AR, Druzin ML, Giardina PJ, Zsebo KM, Adamson JW: Long-term generation of colony-forming cells in liquid culture of CD34+ cord blood cells in the presence of recombinant human stem cell factor. Blood 79:2620, 1992 22. Williams N, Bertoncello I, Kavnoudias H, Zsebo K, McNiece I: Recombinant rat stem cell factor stimulates the amplification and differentiation of fractionated mouse stem cell populations. Blood 79:58, 1992 23. Abboud MR, Xu F, Payne A, Laver J: Effects of recombinant human Steel factor (c-kit ligand) on early cord blood hematopoietic precursors. Exp Hematol 22:388, 1994 24. Steen R, Morkrid L, Tjmnfjord GE, Egeland T: c-kit ligand combined with GM-CSF and/or IL-3 can expand CD34+ hematopoietic progenitor subsets for several weeks in vitro. Stem Cells 12:214, 1994 25. McNiece IK, Langley KE, Zsebo KM: The role of recombinant stem cell factor in early B cell development. Synergistic interaction with IL-7. J Immunol 146:3785, 1991 26. Katayama N, Shih J, Nishikawa S, Kina T, Clark S, Ogawa M: Stage-specific expression of c-kit protein by murine hematopoietic progenitors. Blood 82:2353, 1993 27. Morrissey PJ, Mckenna H, Widmer MB, Braddy S, Voice R, Charrier K, Williams DE,WatsonJD: Steel factor (c-kit ligand) stimulates the in vitro growth of immature CD3-/CD4-/CD8- thymocytes: Synergy with L-7. Cell Immunol 157:118, 1994 28. Molineux G , Migdalska A, Szmitkowski M, Zsebo K, Dexter TM: The effects on hematopoiesis of recombinant stem cell factor (ligand for c-kit) administered in vivo to mice either alone or in combination with granulocyte colony-stimulating factor. Blood 78:961, 1991 29. Ulich TR, del Castillo J, Yi ES, Yin S, McNiece I, Yung YP, Zsebo KM: Hematologic effects of stem cell factor in vivo and in vitro in rodents. Blood 78:645, 1991 30. Bodine DM, Orlic D, Birkett NC, Seidel NE, Zsebo KM: Stem cell factor increases colony-forming unit-spleen number in vitro in synergy with interleukin-6, and in vivo in SllSld mice as a single factor. Blood 79:913, 1992 31. Andrews R, Bartelmez S, Knitter G, Myerson D, Bernstein I, Appelbaum F, Zsebo K: A c-kit ligand, recombinant human stemcell factor, mediates reversible expansion of multiple CD34+ colony-forming cell types in blood and marrowof baboons. Blood 80:920, 1992 32. Bodine DM, Seidel NE, Zsebo KM, Orlic D: In vivo administration of stem cell factor to mice increases the absolute number of pluripotent hematopoietic stem cells. Blood 82445, 1993 From www.bloodjournal.org by guest on January 26, 2015. For personal use only. 4084 33. Hoffman R, Tong J, Brandt J, Traycoff C, Bruno E, McGuire BW, Gordon MS, McNiece 1, Srour EF: The in vitro and in vivo effects of stem cell factor on human hematopoiesis. Stem Cells 276, 1993 34. McNiece IK, Briddell RA, Hartley CA, Smith KA, Andrews RG: Stem cell factor enhances in vivo effects of granulocyte colony stimulating factor for stimulating mobilization of peripheral blood progenitor cells. Stem Cells 2:36, 1993 35. Tong J, Gordon MS, Srour EF, Cooper RJ, Orazi A, McNiece I, Hoffman R: In vivo administration of recombinant methionyl human stem cell factor expands the number of human marrow hematopoietic stem cells. Blood 82:784, 1993 36. Andrews RC, Briddell RA, Knitter CH, Opie T, Bronsden M, Myerson D, Appelbaum FR, McNiece IK: In vivo synergy between recombinant human stem cell factor and recombinant human granulocyte colony-stimulating factor in baboons enhanced circulation of progenitor cells. Blood 84800, 1994 37. Civin Cl, Strauss LC, Brovall C, Fackler MJ, Schwartz JF, Shaper JH: Antigenic analysis of hematopoiesis. 111. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-la cells. J lmmunol 133:157, 1984 38. Ashman LK, Camhareri AC, To LB, Levinsky RJ, Juttner CA: Expression of the YB5.BS antigen (c-kit proto-oncogene product) in normal human hone marrow. Blood 78:30, 1991 39. Papayannopoulou T, Brice M, Broudy VC, Zseho KM: Isolation of c-kit receptor-expressing cells from hone marrow, peripheral blood, and fetal liver: Functional properties and composite antigenic profile. Blood 78:1403, 199I 40. Broudy VC, Lin N, Zseho KM, Birkett NC, Smith KA, Bernstein ID, Papayannopoulou T: Isolation and characterization of a monoclonal antibody that recognizes the humanc-kit receptor. Blood 79338, 1992 4 1. Strobl H, Takimoto M, Majdic 0, Hocker P, Knapp W: Antigenic analysis of human haemopoietic progenitor cells expressing the growth factor receptor c-kit. Br J Haematol 82:287, 1992 42. GunjiY, Nakamura M, Osawa H, Nagayoshi K, Nakauchi H, MiuraY, Yanagisawa M, Suda T: Human primitive hematopoietic progenitor cells are more enriched in KIT'"" cells than in cells. Blood 82:3283, 1993 43. Yamaguchi Y, Gunji Y , Nakamura M, Hayakawa K, Maeda M, Osawa H, Nagayoshi K, Kasahara T, Suda T: Expression of ckit mRNA and protein during the differentiation of human hematopoietic progenitor cells. Exp Hematol 21: 1233, 1993 44. Simmons PJ, Aylett GW, Niutta S, To LB, Juttner CA, Ashman LK: c-kit is expressed by primitive human hematopoietic cells that give rise to colony-forming cells in stroma-dependent or cytokine-supplemented culture. Exp Hematol 22: 157, 1994 45. Briddell RA,BroudyVC. Bruno E, Brandt JE, Srour EF, Hoffman R: Further phenotypic characterization and isolation of human hematopoietic progenitor cells using a monoclonal antibody to the c-kit receptor. Blood 79:3159, 1992 46. Lerner NB, Nocka KH, Cole SR, Qiu FH, Strife A, Ashman LK, Besmer P: Monoclonal antibody YB5.B8 identifies the human c-kit protein product. Blood 77:1876, 1991 47. Liesveld JL, Broudy VC, Harhol AW, Abhoud CN: Effect of stem cell factor on myelopoiesis potential inhuman Dexter-type culture systems. Exp Hematol 23:202, 1995 48. Foxwell BM, Taylor D, Greiner B, Mihatsch MJ, Olivieri V, Ryffel B: Biotinylated recombinant interleukin-2. A tool for research on the interleukin-2 receptor. J Immunol Methods 1 13:231, 1988 49. Newman W, Beall LD, Bertolini DR, Cone JL: Modulation of TGF-0 type 1 receptor: Flow cytometric detection with biotinylated TGF-P. J Cell Physiol 141:170, 1989 50. Taki S, Shimamura T, Abe M, Shirai T, Takahara Y: Biotiny- DE JONG, WAGEMAKER,AND WOGNUM lation of humaninterleukin-2 for Row cytometry analysis of interleukin-2 receptors. J Immunol Methods 12233, 1989 5 1 . Peters DK, Norback DH: Binding and internalization of biotinylated interleukin-2 in human lymphocytes. Blood 76:97, 1990 52. Wognum AW, Lansdorp PM, Humphries RK, Krystal G: Detection and isolation of the erythropoietin receptor using hiotinylated erythropoietin. Blood 76x597, 1990 53. Pieri I, Bamtault D: Biotinylated basic fibroblast growth factor is biologically active. Anal Biochem 195:214, 1991 54. de Jong MO, Rozemuller H, Visser JWM, Bauman JGJ: A sensitive method to detect cell surface receptors using biotinylated growth factors. Prog Histochem Cytochern 26:119, 1992 55. Wognum AW, Krystal G, Eaves CJ, Eaves AC, Lansdorp PM: Increased erythropoietin-receptor expression on CDW-positive honemarrow cells from patients with chronic myeloid leukemia. Blood 79542, 1992 56. Wognum AW, van Gils FCJM, Wagemaker G: Flow cytometric detection of receptors for interleukin-6 onbonemarrowand peripheral blood cells of humans and rhesus monkeys. Blood 81:2036, 1993 57. Wognum AW, Westerman Y, Visser TP, Wagemaker G: Distribution of receptors for granulocyte-macrophage colony-stimulating factor on immature CD34+ hone marrow cells, differentiating monomyeloid progenitors, and mature bloodcell subsets. Blood 84:764, I994 58. WognumAW,Visser TP, de Jong MO,Egeland T, Wagemaker G: Differential expression of receptors for interleukin-3 on suhsets of CD34-expressing hematopoietic cells of rhesus monkeys. Blood 86381, 1995 59. de Jong MO, Rozemuller H, Bauman JGJ, Visser JWM: Biotinylation of interleukin-2 (IL-2) for flow cytometric analysis of IL2 receptor expression: Comparison of different methods. J Immunol Methods 184: 10 I , 1995 60. Avanzi GC, Lista P, Giovinazzo B, Miniero R, Saglio G, BenettonG, Coda R, Cattoretti G, Pegoraro L: Selective growth response to IL-3 of a human leukaemic cell line with megakaryoblastic features. Br J Haematol 69:359, 1988 61. Hendrie PC, Miyazawa K,YangYC,Langefeld CD, Broxmeyer HE: Mast cell growth factor (c-kit ligand) enhances cytokine stimulation of proliferation of the human factor-dependent cell line, M07e. Exp Hematol 19: 1031, 1991 62. Dicke KA, Lina PH, van Bekkum DW: Adaptation of albumin density gradient centrifugation to human bone marrow fractionation. Rev EurEtud Clin Biol 15:305, 1970 63. Blackett NM: Statistical accuracy to he expected from cell colony assay; with special reference to the spleen colony assay. Cell Tissue Kinet 7:407, 1974 64. lscove NN: The role of erythropoietin in regulation of population size and cell cycling of early and late erythroid precursors in mouse hone marrow. Cell Tissue Kinet 10:323, 1977 65. Okada S, Nakauchi H, Nagayoshi K, Nishikawa S, Nishikawa S. Miura Y, Suda T: Enrichment and characterization ofmurine hematopoietic stem cells that express c-kit molecule. Blood 78: 1706. 1991 66. lkuta K, Weissman IL: Evidence that hematopoietic stem cells express mouse c-kit but do not depend on steel factor for their generation. Proc Natl Acad Sci USA 89: 1502, I992 67. Okada S, Nakauchi H, Nagayoshi K, Nishikawa S, Miura Y, Suda T: In vivo and in vitro stem cell function of c-kit- and ScaI -positive murine hematopoietic cells. Blood 80:3044. 1992 68. Ogawa M, Shih JP, Katayama N: Enrichment for primitive hemopoietic progenitors of marrowcells from 5-fluorouracil-treated mice and normal mice. Blood Cells 20:7, 1994 69. Daj CH, Krantz SB, Zseho KM: Human burst-forming units- From www.bloodjournal.org by guest on January 26, 2015. For personal use only. c-kit DISTRIBUTION ON HEMATOPOIETIC CELLS erythroid need direct interaction with stem cell factor for further development. Blood 78:2493, 1991 70. Loken MR, Shah VO, Dattilio KL, Civin CI: Flow cytometric analysis of human bone marrow: I. Normal erythroid development. Blood 69:255, 1987 71. Wickrema A, Krantz SB, Winkelmann JC, Bondurant MC: Differentiation and erythropoietin receptor gene expression in human erythroid progenitor cells. Blood 801940, 1992 72. Ogawa M, Matsuzaki Y, Nishikawa S, Hayashi S, Kunisada T, Sudo T, Kina T, Nakauchi H, Nishikawa S: Expression and functionof c-kit in hemopoietic progenitor cells. J Exp Med 174:63, 1991 73. Nishikawa S, Kusakabe M, Yoshinaga K, Ogawa M, Hayashi S, Kunisada T, Era T, Sakakura T, Nishikawa S: In utero manipula- 4085 tion of coat color formation by a monoclonal anti-c-kit antibody: Two distinct waves of c-kit-dependency during melanocyte development. EMBO J 10:21ll, 1991 74. Brandt J, Baird N, Lu L, Srour E, Hoffman R: Characterization of a human hematopoietic progenitor cell capable of forming blast cell containing colonies in vitro. J Clin Invest 82:1017, 1988 75. Sutherland H, Eaves C, Lansdorp P, Thacker J, Hogge D: Differential regulation of primitive human hematopoietic cells in long-term cultures maintained on genetically engineered murine stromal cells. Blood 78:666, 1991 76. Orlic D, Fischer R, Nishikawa S, Nienhuis AW, Bodine DM: Purification and characterization of heterogeneous pluripotent hematopoietic stem cell populations expressing high levels of c-kit receptor. Blood 82:762, 1993 From www.bloodjournal.org by guest on January 26, 2015. For personal use only. 1995 86: 4076-4085 Separation of myeloid and erythroid progenitors based on expression of CD34 and c-kit MO De Jong, G Wagemaker and AW Wognum Updated information and services can be found at: http://www.bloodjournal.org/content/86/11/4076.full.html Articles on similar topics can be found in the following Blood collections Information about reproducing this article in parts or in its entirety may be found online at: http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests Information about ordering reprints may be found online at: http://www.bloodjournal.org/site/misc/rights.xhtml#reprints Information about subscriptions and ASH membership may be found online at: http://www.bloodjournal.org/site/subscriptions/index.xhtml Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly by the American Society of Hematology, 2021 L St, NW, Suite 900, Washington DC 20036. Copyright 2011 by The American Society of Hematology; all rights reserved.
© Copyright 2024